{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID&page=35",
    "query": {
      "condition": "COVID",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1208,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T06:33:44.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04344184",
      "title": "SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Lung Injury, Acute",
        "Kidney Injury"
      ],
      "interventions": [
        {
          "name": "L-ascorbic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2020-12-18",
      "completion_date": "2022-06-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04344184"
    },
    {
      "nct_id": "NCT04349410",
      "title": "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "CoVid 19 Positive"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine, Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin, Primaquine - low dose.",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin, Primaquine - high dose.",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Interferon-Alpha2B",
          "type": "DRUG"
        },
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Convalescent Serum",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Camelot Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1800,
      "start_date": "2020-04-11",
      "completion_date": "2020-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04349410"
    },
    {
      "nct_id": "NCT04401410",
      "title": "Anti-SARS Cov-2 T Cell Infusions for COVID 19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV 2",
        "Viral Infection",
        "COVID 19"
      ],
      "interventions": [
        {
          "name": "Dose Finding Phase (MTD)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Partially HLA-matched SARS-CoVSTs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine care (no SARS-CoVSTs)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2020-11-04",
      "completion_date": "2021-10-12",
      "has_results": false,
      "last_update_posted_date": "2022-12-19",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401410"
    },
    {
      "nct_id": "NCT05877508",
      "title": "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Post-Acute Sequela of COVID-19",
        "Post-Acute COVID-19"
      ],
      "interventions": [
        {
          "name": "AER002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Michael Peluso, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2023-08-01",
      "completion_date": "2026-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877508"
    },
    {
      "nct_id": "NCT04723602",
      "title": "Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Disease",
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "cAd3-Marburg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cAd3-EBO-S",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Albert B. Sabin Vaccine Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2021-01-06",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04723602"
    },
    {
      "nct_id": "NCT05477186",
      "title": "Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV0501 (3 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (6 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (12 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (25 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (50 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (100 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (200 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2022-08-12",
      "completion_date": "2023-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477186"
    },
    {
      "nct_id": "NCT05506618",
      "title": "Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Nasal Swab",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Nasopharyngeal swab",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "LumiraDx UK Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 758,
      "start_date": "2022-06-30",
      "completion_date": "2022-10-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Hawthorne, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hawthorne",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Gresham",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05506618"
    },
    {
      "nct_id": "NCT04424446",
      "title": "Saliva as Source of Detection for SARS-CoV-2",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2020-07-13",
      "completion_date": "2020-09-04",
      "has_results": false,
      "last_update_posted_date": "2021-06-02",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424446"
    },
    {
      "nct_id": "NCT04969991",
      "title": "Study of Varespladib in Patients Hospitalized With Severe COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019",
        "Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2"
      ],
      "interventions": [
        {
          "name": "Varespladib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophirex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-06-30",
      "completion_date": "2022-11-22",
      "has_results": true,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 7,
      "location_summary": "Ventura, California • Miami, Florida • Munster, Indiana + 3 more",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969991"
    },
    {
      "nct_id": "NCT06257420",
      "title": "Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myalgic Encephalomyelitis",
        "Long-COVID"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Simmaron Research Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 150,
      "start_date": "2023-12-11",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-29T06:33:44.431Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Rochester, Minnesota • Incline Village, Nevada + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Incline Village",
          "state": "Nevada"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06257420"
    }
  ]
}